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Background: The soluble interleukin-2 receptor (sIL-2R, sIL2R, sTAC, sCD25) is a reliable biomarker for disease
activity in inflammatory disorders such as sarcoidosis. Based on the essential pathogenic role of inflammation for
progression of liver diseases, we hypothesized that sIL-2R might be an indicator of inflammatory cell activation and
disease severity in patients with chronic liver diseases (CLD).
Methods: We measured sIL-2R serum levels in 71 patients with different stages and etiologies of CLD in
comparison to 41 healthy controls. Serum sIL-2R concentrations were correlated with laboratory markers of liver
diseases, cytokine / chemokine levels and circulating immune cell subpopulations as simultaneously assessed by
FACS analysis from peripheral leukocytes.
Results: CLD patients showed significantly elevated serum sIL-2R levels compared with controls. sIL-2R was
significantly higher in patients with compared to patients without established liver cirrhosis and increased with the
Child-Pugh stage of cirrhosis, independent of the underlying etiology. sIL-2R levels correlated inversely with
parameters indicating the hepatic biosynthetic capacity, such as albumin or international normalized ratio, and
positively with non-invasive markers of liver fibrosis such as hyaluronic acid or procollagen-III-peptide. Circulating
immune cells might represent a major source of sIL-2R. In fact, sIL2-R levels correlated closely with circulating
monocytes, especially non-classical CD14+ CD16+ monocytes, which were found to express high levels of CD25 by
FACS. Pro-inflammatory cytokines, including IL-2, IFNγ or IL-6, and chemokines were also associated with sIL2-R. In
addition, renal failure was an important confounder of sIL-2R levels independent of liver dysfunction and
inflammation.
Conclusions: sIL-2R is elevated in patients with liver diseases and cirrhosis, is associated with circulating
inflammatory cells and is increased in concomitant renal failure. These data indicate that sIL-2R might be a potential
marker for immune cell activation in CLD, especially for proinflammatory and profibrogenic non-classical
CD14 + CD16+ monocytes.
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Since its discovery in 1985 the soluble interleukin-2 recep-
tor (sIL-2R, sTAC, sCD25) has become a clinically valuable
tool for several diseases [1]. It is regarded as a disease
activity marker in sarcoidosis [2,3], but increased serum
levels have been also observed in other autoimmune
diseases like systemic lupus erythematosus and rheumatoid* Correspondence: frank.tacke@gmx.net
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reproduction in any medium, provided the orarthritis [4]. In addition, sIL-2R is elevated in several
neoplastic disorders, and it appears useful in estimating
survival and monitoring therapy in malignancies like
malignant melanoma or nasopharyngeal carcinoma [5,6].
While interleukin-2 is primarily secreted by activated
T-helper lymphocytes [7,8], the interleukin-2 receptor
(IL-2R, CD25) is widely expressed among many leuko-
cytes. Although activated T lymphocytes and regulatory
T cells express high levels of IL-2Rα, which is part of
the IL-2receptor, on their surface [8-12], it is well
known that activated B cells, monocytes, eosinophilLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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press CD25 [13-17]. The soluble form of the IL-2
receptor seems to be produced by proteolytic cleavage
of IL-2Rα, and the release of sIL-2R into the circulation
has been found to be proportional to its membrane
bound expression [3,16,18]. This is regarded as the
main reason why sIL2-R is a reliable biomarker for
disease activity in inflammatory disorders, especially in
sarcoidosis and other autoimmune diseases.
Due to its close association with inflammatory processes,
sIL-2R could be possibly a useful marker in chronic liver
diseases (CLD), given the fact that chronic inflammation is
believed to be the key driver for disease progression
[19,20]. There are some studies examining sIL-2R in CLD
suggesting increased sIL-2R in hepatic disorders [21,22].
However, a major drawback of these studies is that they
focused on selected etiologies, predominantly viral-related
liver diseases or primary biliary cirrhosis [21-24]. It thus
remained unclear whether sIL-2R may be universally use-
ful to monitor inflammatory activities in progressing CLD
and to which extent sIL-2R may reflect activation of
distinct leukocyte subpopulations in CLD. In the current
work we measured sIL-2R levels in 71 patients with differ-
ent stages and a wide spectrum of etiologies of chronic
hepatic disorders in comparison to 41 healthy controls.
We analyzed whether sIL-2R serum levels correlated with
clinical and routine laboratory markers of liver diseases,
but also with experimental cytokine and chemokine levels
or circulating immune cell subpopulations as simultan-
eously assessed by FACS analysis from peripheral leuko-
cytes. We hypothesized that sIL-2R might be a general
indicator of inflammatory cell activation in CLD patients.
Materials & methods
Study participants
The local ethics committee (ethics committee of University
Hospital Aachen, RWTH Aachen) approved the study
protocol, and written informed consent was obtained from
each participant. Patients (n= 71) with chronic liver
disease (CLD) independent of the etiology were enrolled in
the present study. Patient characteristics are summarized
in Table 1. 48 patients showed overt signs for cirrhosis
confirmed by imaging (MRI, CT scan or ultrasound) or
cirrhosis related complications (e.g. esophageal varices or
encephalopathy) [25]. Patients with acute liver failure,
acute hepatitis, HIV infection, bacterial infection (procalci-
tonin above 0.5 μg/l) and systemic steroid medication were
excluded. Furthermore, patients with malignant tumors
and with hepatocellular carcinoma were excluded, because
malignancies are known to increase sIL2-R levels [5,6].
Healthy controls (n= 41) were recruited from the local
blood transfusion institute and from the staff of the
Department of Medicine III of the University Hospital
Aachen, Germany. They were tested negatively for HIV,HBV and HCV infections. Peripheral blood samples were
collected from all study participants by venipuncture.
Blood was processed for immediate FACS analysis, while
sera were stored at −80°C until analysis.
Analysis of circulating leukocytes via flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated
by Ficoll Density Gradient, as described before [26,27]. In
brief, after centrifugation at 2200 rpm for 20 minutes at
20 ° C using LSM 1077 Lymphocyte Separation Medium
(PAA, Pasching, Austria), the intermediate layer consisting
of PBMC was washed twice in HANKS's medium (PAA)
containing 0.1% BSA and 0.5 mM EDTA. The procedure
was repeated twice with DMEM Buffer (PAA) containing
2 mM EDTA and 0.5% BSA. After inhibiting nonspecific
antibody binding, the following monoclonal antibodies
and appropriate isotype controls were used for flow cytom-
etry: CD3, CD4, CD8, CD56, CD14, CD16, CD56, CD25
and CD19 (all BD). A FACS Canto-II (BD) was used for
flow cytometric analysis. The acquired data were analyzed
by FlowJo software (TreeStar, Ashland, OR). Numbers of
circulating cells were calculated by the percentage of the
respective cell subset multiplied by the respective subset of
absolute cell count obtained from routine blood count.
Measurements of cytokines and chemokines
Concentrations of cytokines and chemokines (IL-1β, IL-2,
IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IFNγ, G-CSF, TNFα,
TNFβ, CCL2, CCL3, CCL4, CXCL9, CXCL10) were
measured using Flow Cytomix (eBiosciences) as described
before [26]. Fractalkine (CX3CL1) was measured by ELISA
(BD) [28].
Measurements of sIL-2R
Concentrations of sIL-2R were measured using Immulite
1000 IL-2R, a solid-phase, two-site chemiluminescent
immunometric assay, according to the manufacturer’s
instructions (Siemens, Erlangen, Germany).
Statistics
Box-and-whiskers plots were used to display data graph-
ically. The box-and-whiskers plots show the statistical
summary of the median (bold line), quartiles (boxes),
range and extreme values. The whiskers extend from
the minimum to the maximum value excluding outside
(>1.5 times upper/lower quartile, open circle) and
"far out" (>3 time upper/lower quartile, asterixes) values
which are displayed separately [29]. Correlations
between parameters were assessed by Spearman rank
correlation test. Moreover, multivariate regression
analyses were performed in order to determine which of
the parameters independently influence sIL-2R levels
[30]. Comparisons of parameters between two different
groups were conducted with the Mann–Whitney-U-test.
Table 1 Patient characteristics and sIL-2R measurements
controls all
patients
stage of cirrhosis
no cirrh. Child A Child B Child C
n 41 71 23 21 13 14
sex male/ female n 20/21 37/34 11/12 8/13 8/5 10/4
age yrs 35 54 43 61 63 53
median (range) (18–65) (17–74) (17–64) (30–74) (28–74) (34–73)
disease etiology n n.a.
virus hepatitis 24 11 8 5 0
biliary/autoimmune 8 2 4 1 1
alcohol 21 3 5 3 10
other origin 18 7 4 4 3
MELD score n.a. n.a. n.a. 8 11 17
median (range) (6–17) (7–16) (12–28)
ALT U/L 19 41 64 34 36 29
median (range) (5–54) (7–568) (15–568) (8–188) (7–92) (14–261)
bilirubin mg/dL n.a. 1.3 0.7 0.9 1.6 5.1
median (range) (0.2-12.5) (0.4-8.7) (0.2-8.9) (0.2-9.0) (1.8-12.5)
albumin mg/dL n.a. 38 45 40 27 27
median (range) (12–50) (40–50) (30–43) (12–38) (22–31)
international normalized n.a. 1.07 0.98 1.06 1.20 1.43
ratio median (range) (0.92-1.69) (0.93-1.12) (0.92-1.32) (0.99-1.39) (1.18-1.69)
hyaluronic acid μg/l n.a. 190 28 205 305 800
median (range) (10–800) (10–210) (36–800) (140–800) (190–800)
procollagen-III-peptide 584 1135 973 990 1710 2500
median (range) μg/l (157–1160) (470–6560) (470–1750) (589–1930) (639–2630) (1010–6560)
creatinine mg/dL 0.7 0.7 0.7 0.7 0.6 0.8
median (range) (0.6-0.9) (0.3-2.4) (0.4-1.0) (0.4-1.9) (0.4-1.8) (0.3-2.4)
cystatin C mg/L n.a. 0.98 0.80 1.01 1.20 1.46
median (range) (0.40-2.81) (0.40-1.16) (0.69-2.81) (0.74-2.78) (0.80-2.41)
GFR [cyst. C] ml/min n.a. 88 123 83 64 45
median (range) (15–395) (66–395) (15–158) (15–140) (19–123)
total monocytes x106/L 416 490 419 426 477 816
median (range) (165–852) (70–2208) (70–860) (296–1332) (162–2208) (294–1180)
CD14++CD16- monocytes 386 442 384 387 425 714
x106/L median (range) (155–748) (65–2101) (65–807) (250–1155) (142–2101) (257–1089)
CD14+CD16+ monocytes 32.4 46 40 45 67 92
x106/L median (range) (10–108) (4.6-175) (4.6-158) (26–175) (18–135) (6.4-153)
sIL-2R kU/L 444 818 374 764 1101 1029
median (range) (14–1193) (39–3976) (204–1795) (39–3976) (317–2494) (370–3350)
ALT, alanine aminotransferase activity; GFR, glomerular filtration rate; MELD, model of end-stage liver disease; n.a., not applicable / not assessed; sIL-2R, soluble
interleukin-2 receptor.
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http://www.biomedcentral.com/1471-230X/12/38Comparisons between more than two groups were done
with the Kruskal-Wallis analysis of variances (ANOVA),
followed by Mann–Whitney-U-tests for post hoc
analysis. All analyses were two-tailed and p values <0.05
were considered as statistically significant. The levels
of significance are indicated in the figures as followed:
* p< 0.05, ** p< 0.01, ***p< 0.001. Statistical analyses
were performed using SPSS (SPSS, Chicago, IL).Results
sIL-2R is elevated in chronic liver disease
Serum levels of sIL-2R have been suggested to reflect
activation of immune cells in various inflammatory ormalignant diseases [1-4,31]. Elevated sIL-2R has been
reported for distinct hepatic disorders such as viral hepa-
titis or primary biliary cirrhosis as well, but the clinical
significance of this finding remained vague [23,24]. We
therefore measured serum sIL-2R levels in 71 patients
with chronic liver diseases (CLD), which had no signs of
concomitant infections (clinically, and negative testing
for procalcitonin) and no signs of malignancies
(especially hepatocellular or cholangiocellular carcin-
omas). In comparison to 41 healthy controls, CLD
patients showed significantly elevated serum sIL-2R
levels (median 444 kU/L, range 14–1193, vs. median 818
kU/L, range 39–3976; Figure 1A, Table 1). Importantly,
sIL-2R was only increased in patients with established
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Figure 1 sIL-2R levels increase in patients with chronic liver disease and are associated with disease progression. Box plots display serum
levels of sIL-2R in kU/L for healthy controls versus patients with chronic liver diseases (A), patients without cirrhosis versus cirrhotic
patients (B), study participants according to Child-Pugh score (C), and mild versus advanced CLD (D). (E) Levels of sIL-2R correlate
with procollagen-III-peptide (r = 0.514, p< 0.001, Spearman rank correlation test). (F) Serum sIL-2R concentrations do not differ among
various etiologies of CLD. Significant differences (Kruskal-Wallis and U-test) are marked by *p< 0.05, **p< 0.01, ***p< 0.001. Open
circles and asterixes at the whiskers indicate outlier values.
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http://www.biomedcentral.com/1471-230X/12/38liver cirrhosis (median 374 kU/L, range 204–1795, vs.
median 907 kU/L, range 39–3975, Figure 1B), but did
not differ between non-cirrhotic patients and controls
(Figure 1C). We observed increasing sIL-2R levels with
the stage of liver cirrhosis, as assessed by the Child-Pugh
score (Figure 1C). In fact, patients with advanced or
decompensated cirrhosis, staged Child B and C, had sig-
nificantly higher sIL-2R concentrations than patients with-
out cirrhosis or with early cirrhosis (median 600 kU/L,
range 39–3976, vs. median 1101 kU/L, range 317–3395,
Figure 1D). By ROC curve analysis, sIL-2R could discrim-
inate between non-cirrhotic vs cirrhotic patients (area
under the curve [AUC]= 0.755, detailed data not shown).In line, sIL-2R levels correlated inversely with para-
meters indicating the hepatic biosynthetic capacity, such
as albumin (r = −0.496, p< 0.001), pseudocholinesterase
activity (r =−0.484, p< 0.001) or international normalized
ratio (INR, r = 0.349, p = 0.003, Table 2). Non-invasive
markers of liver fibrosis such as hyaluronic acid (r = 0.383,
p = 0.003) or procollagen-III-peptide (r = 0.514, p< 0.001,
Figure 1E) correlated positively with sIL-2R, emphasizing
that sIL-2R is associated with disease progression in CLD
patients and may therefore serve as a non-invasive tool to
stratify disease severity. Interestingly, serum sIL-2R
concentrations were independent of the underlying
etiology of chronic liver disease (Figure 1F), indicating
Table 2 Correlation analysis
sIL-2R in liver disease patients
(n = 71)
r p
Liver Function
albumin −0.496 <0.001
pseudocholinesterase −0.484 <0.001
international normalized ratio 0.349 0.003
bilirubin 0.265 0.025
alkaline phosphatase 0.248 0.037
Hepatic fibrosis
hyaluronic acid 0.383 0.003
procollagen-III-peptide 0.514 <0.001
Inflammation
total monocytes 0.366 0.002
CD14++CD16- monocytes 0.332 0.006
CD14+CD16+ monocytes 0.402 0.001
IL-2 0.310 0.010
IL-4 0.271 0.025
IL-6 0.476 0.000
IL-8 (CXCL8) 0.308 0.011
IL-10 0.388 0.001
IFNγ 0.297 0.014
G-CSF 0.239 0.049
MIP1α (CCL3) 0.359 0.002
MIP1β (CCL4) 0.244 0.045
MIG (CXCL9) 0.329 0.006
IP-10 (CXCL10) 0.340 0.005
fractalkine (CX3CL1) 0.398 0.001
Renal Function
cystatin C 0.603 <0.001
creatinine 0.301 0.011
urea 0.266 0.026
sIL-2R serum concentrations were correlated with various routine and
experimental laboratory parameters. Only significant correlations are shown.
Spearman rank correlation test, p< 0.05.
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http://www.biomedcentral.com/1471-230X/12/38that only CLD disease severity, but not the nature of
the initial insult determined sIL-2R levels.sIL2-R serum levels are associated with circulating
monocytes and inflammatory cytokines
As a source of circulating sIL-2R, various immune cells
including T-cells or monocytes have been postulated
[13-17]. We thus analyzed circulating leukocytes in our
patient cohort by FACS analysis. Of note, blood mono-
cytes consist of two principal subsets, termed ‘classical’
and ‘non-classical’ monocytes, which are characterized
by the expression of CD14++ or CD14+CD16+, respect-
ively [26]. By FACS analysis, we confirmed that not only
activated T-cells, but also monocytes expressed IL-2R(CD25) (Figure 2A). In comparison to classical CD14++
monocytes, the ‘non-classical’ CD14+CD16+ monocytes
expressed higher levels of CD25 on their surface
(Figure 2A). In accordance with previous findings
reported by our group [27], monocytes and especially the
non-classical (‘proinflammatory’) CD14+CD16+ mono-
cyte subpopulation increased in patients with liver dis-
ease in association with disease progression (Figure 2B,
Additional file 1: Figure S1), while NK-, T- and B-lym-
phocytes were not elevated in CLD patients (Table 1,
and data not shown). Serum sIL-2R concentrations did
not correlate with NK-, T- or B-lymphocytes or their re-
spective subpopulations, e.g. CD4+ or CD8+ T-cells.
However, sIL-2R levels correlated with circulating mono-
cytes and their subfractions. Serum sIL-2R concentra-
tions correlated not only with total monocyte counts,
but also with the classical (CD14++CD16-) and non-clas-
sical (CD14+CD16+) monocyte subset (Figure 2C,
Table 2). The closest correlation was found between sIL-
2R and the non-classical CD14+CD16+ monocytes
(r = 0.402, p = 0.001, Figure 2C).
In addition, sIL-2R correlated with various pro-
inflammatory cytokines, including IL-2 itself, IFNγ or
IL-6, but also with pro-inflammatory chemokines
such as CCL3, CCL4, CXCL8, CXCL9, CXCL10,
CX3CL1 and others (Table 2). Most of these chemo-
kines have been linked to either monocyte or T-cell
activation as well as to trafficking of monocytes or
T-cells [32]. However, in our study cohort sIL-2R
was more closely correlated to circulating monocytes
and especially the ‘inflammatory’ CD14+ CD16+subset
than other cytokines and chemokines (data not
shown). Thus, our data indicated that monocytes or
macrophages might contribute to circulating sIL-2R
levels in patients with chronic liver diseases and that
sIL-2R levels are associated with inflammatory pro-
cesses present in patients with cirrhosis.
Renal dysfunction is an additional determinant of sIL2-R
serum levels in patients with chronic liver diseases
Besides its association with inflammatory cells, sIL-2R
has been demonstrated to be metabolized and cleared
via the kidney in animal models [3]. In line, patients with
renal failure were found to have elevated sIL-2R levels as
well [33,34]. Due to the fact that decreased glomerular
filtration is a condition commonly found in patients with
CLD [35], we aimed at verifying the association between
sIL-2R levels and liver disease severity as well as circulat-
ing monocytes and inflammatory markers by addressing
renal function as a confounding factor. Indeed, we found
a clear inverse correlation between serum sIL-2R and the
glomerular filtration rate as well as positive correlations be-
tween sIL-2R and creatinine, cystatin C or urea (Figure 3A,
Table 2). When levels of sIL-2R were normalized to renal
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http://www.biomedcentral.com/1471-230X/12/38function by calculating the ‘sIL-2R/cystatin C ratio’, no dif-
ference could be detected anymore between patients with-
out or with liver cirrhosis (Figure 3B). However, the
correlation between sIL-2R and non-classical monocytes
remained significant even after applying the ‘sIL-2R/cystatin
C ratio’ (Figure 3C).
In order to assess which of the factors is predominant
for regulating sIL-2R levels in patients with chronic liver
diseases, a multivariate regression analysis was performed,
using sIL-2R as the dependent variable and markers of
liver function (albumin, INR, pseudocholinesterase),
fibrosis (procollagen-III-peptide), inflammation (IL-6) and0
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http://www.biomedcentral.com/1471-230X/12/38demonstrated that sIL-2R reflects the activation of
immune cells [1-4,31]. Only few studies examined sIL-2R
in chronic liver diseases, and most of these focused on
distinct hepatic disorders such as viral hepatitis or
primary biliary cirrhosis [23,24]. Based on the essential
pathogenic role of inflammation for the progression of
liver injury and fibrosis [32], we hypothesized that sIL-
2R might be an indicator of inflammatory cell activation
and disease severity in patients with chronic liver
diseases (CLD). Strikingly, sIL-2R concentrations were
significantly elevated in chronic liver diseases independ-
ent of the underlying etiology, associated with the stage
of liver cirrhosis and correlated to other established
biomarkers of liver function and hepatic fibrosis.
In line with assumptions from non-hepatic inflamma-
tory disorders such as sarcoidosis [2], we speculated that
sIL-2R in serum is mainly the result of shedding from
the surface of activated immune cells. The thorough
comparison of serum sIL-2R levels with flow-cytometric
phenotyping of freshly isolated PBMC in CLD patients
unexpectedly revealed a close association of sIL-2R with
monocytes, specifically with the non-classical CD14
+CD16+ monocyte subset. Several recent studies from
animal models have provided evidence that monocytes
that infiltrate the injured liver from the circulation are a
crucial pathogenic factor for the progression of liver
fibrosis [19,36,37]. In order to translate observations
from animal models into human pathogenesis, we had
previously studied peripheral and intrahepatic monocytes
and macrophages from CLD patients and were able to
demonstrate that monocytes, especially the non-classical
CD14+CD16+ subset, significantly increase with disease
progression [27]. These CD14+CD16+ monocytes are
prone to release important pro-inflammatory cytokines
as well as chemokines and are even capable of directly
activating collagen-producing hepatic stellate cells, thus
suggesting distinct pro-inflammatory and pro-fibrogenic
properties of this monocyte subset in vivo [27]. However,
the direct flow-cytometric analysis of monocyte subsets
is technically demanding, time-consuming and costly
[26]. The striking correlation between sIL-2R and (non-
classical) monocytes raises the possibility that sIL-2R
could serve as a surrogate marker for monocyte subset
alterations. It was moreover remarkable that only mono-
cyte and monocyte subpopulations, but not peripheral
neutrophils, NK-, B- or T-lymphocytes, correlated with
sIL-2R, further indicating that monocytes are an import-
ant source of sIL-2R in patients with liver cirrhosis.
However, our study also revealed that sIL-2R levels are
strongly influenced by renal function, suggesting a renal
clearance of sIL-2R in humans. This is not surprising,
because Junghans et al. had shown that the kidney
mainly catabolizes sIL-2R in mice, followed by filtra-
tion and excretion [3]. We thus used cystatin C as abiomarker to detect early renal impairment in patients
with liver dysfunction [35]. In fact, sIL-2R correlated
with the glomerular filtration rate calculated from
cystatin C, and some of the detected differences for
sIL-2R between non-cirrhotic and cirrhotic patients
vanished after normalization to renal function. Import-
antly, the significant correlation between the non-classical
monocytes and sIL-2R was unaffected by renal failure, as
evidence by normalization calculations as well as multi-
variate analysis.
Conclusions
Serum concentrations of sIL-2R are elevated in
patients with liver diseases and cirrhosis. Renal failure
is an important confounding factor for sIL-2R levels
in liver disease patients. sIL-2R levels are associated
with cytokine and chemokine concentrations as well
as circulating inflammatory cells, especially from the
monocyte lineage. These data indicate that sIL-2R
might be a potential marker for immune cell activa-
tion in CLD, especially for proinflammatory and
profibrogenic non-classical CD14+CD16+ monocytes.
Further studies are warranted that evaluate sIL-2R
levels prospectively as a potential biomarker for
fibrosis progression and that elucidate the possible
functional contribution of circulating IL-2 receptor to
immune cell attraction or activation.
Additional file
Additional file 1: Figure S1. Frequencies of circulating monocytes and
monocyte subsets are elevated in chronic liver disease (CLD). (A) The
frequencies of total monocytes (defined as CD14+ cells) and monocyte
subpopulations were measured by FACS analysis. The amount of
circulating monocytes relative to all peripheral blood mononuclear cells
(PBMC) was significantly higher (***p< 0.001) in patients with CLD than
in healthy controls. Single values and median are depicted. (B) Absolute
numbers of circulating monocytes differ between controls and patients
with CLD (*p< 0.05). (C-D) Absolute counts of circulating ‘classical’ CD14+
+CD16- (C) and ‘non-classical’ CD14 +CD16+ (D) monocyte subsets are
significantly augmented in patients with CLD (*p< 0.05 and **p< 0.01,
respectively).
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